Introduction {#s1}
============

Probiotics are living microorganisms that confer a health benefit on the host upon ingestion in adequate amounts [@pone.0060007-Khani1], [@pone.0060007-Kelly1]. Lactic acid bacteria are a large group of bacteria that produce lactic acid as an end product of fermentation. They are commonly used as probiotics because they have long been used in food production and they are safe for human consumption [@pone.0060007-Vanderhoof1]. While the mechanisms remain unclear, clinical studies have demonstrated that supplementation of lactic acid bacteria as a probiotic can significantly reduce the incidence of neonatal necrotizing enterocolitis (NEC), a devastating disease affecting about 5--7% of infants with a birth weight less than 1500 grams and one of the significant causes of mortality and morbidity in premature infants [@pone.0060007-Neu1], [@pone.0060007-Fanaroff1], [@pone.0060007-Lin1], [@pone.0060007-Deshpande1].

Therapeutic designs aiming at promoting neonatal intestinal mucosa maturation and protection have become a strategy for prevention and treatment of NEC. A central question is how to effectively deliver therapeutic agents such as mucosa protective factors, anti-inflammatory cytokines or anti-infective agents to the neonatal gut. In the past two decades, whereas significant advances have been made in using Lactococcus as a vehicle to deliver therapeutic agents to the GI tract, in part because expression of exogenous proteins in Lactococcus is well established [@pone.0060007-Steidler1], [@pone.0060007-Wells1], use of Lactobacillus in this aspect has lagged behind. In particular, expression of exogenous proteins at a high level in Lactobacillus has long been a challenge. However, Lactobacillus offers some advantages over Lactococcus. For example, Lactobacillus species are commensals of the human gut while Lactococcus species are not [@pone.0060007-Marteau1]. In addition, Lactobacillus species typically have a temperature range of 37--41°C for optimal growth, close to the normal human body temperature, compared with 25--30°C for Lactococcus [@pone.0060007-Duwat1]. Further, for certain popular diary products such as yogurt, Lactobacillus but not Lactococcus has been commonly used as a starter culture. As a result, we aimed at developing a Lactobacillus-based system to deliver therapeutic agents to the gastrointestinal tract of neonates. In this work, we used mRFP1, a red fluorescent protein, as a reporter to examine the impact of three different promoters and two different backbones on the expression level of mRFP1. In addition, we used mRFP1 as a marker to label Lactobacillus and examined the retention rate of the recombinant Lactobacillus in the GI tract of neonatal rats.

Materials and Methods {#s2}
=====================

Bacteria {#s2a}
--------

The following Lactobacillus strains were used for this work: *Lactobacillus casei subsp. casei* (ATCC 27139^™^), *Lactobacillus acidophilus* (ATCC 11976^™^) and *Lactobacillus delbrueckii subsp. bulgaricus* (ATCC 11842^™^) ([Table 1](#pone-0060007-t001){ref-type="table"}). All these strains were purchased from ATCC (Manassas, Virginia). The *Escherichia coli* DH5α strain was purchased from Life Technologies (Grand Island, New York). Lactobacillus was cultured at 37°C in de Man-Rogosa-Sharpe (MRS) medium (BD-Difco, New Jersey). *E. coli* was cultured in the Circlegrow medium (MP Biomedicals, California). Transformation of *E. coli* followed a standard procedure [@pone.0060007-Sambrook1]. Transformed *E. coli* was selected in the presence of 100 µg/ml ampicillin.
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###### Summary of bacterial strains and plasmids used in this work.

![](pone.0060007.t001){#pone-0060007-t001-1}

  Strains/plasmids                                                                    Features                                        References or sources
  ------------------------------------------------- ---------------------------------------------------------------------------- --------------------------------
  **Bacterial strains**                                                                                                          
  *Lactobacillus casei subsp. Casei*                                            Transformation host                                       ATCC 27139^™^
  *Lactobacillus acidophilus*                                                   Transformation host                                       ATCC 11976^™^
  *Lactobacillus delbrueckii subsp*. *Bulgaricus*                               Transformation host                                       ATCC 11842^™^
  *Escherichia coli DH5α*                                                       Transformation host                                     Life Technologies
  **Plasmids**                                                                                                                   
  pRV85                                                                  Emr, containing the dhlL promoter                          Ref. [@pone.0060007-Gory1]
  pRSET~B~-mRFP1                                                      Ampr, containing the FLAG-mRFP1 sequence                    Ref. [@pone.0060007-Campbell1]
  pLEM415                                                         Emr, Ampr; E. coli-Lactobacillus shuttle vector                   Ref. [@pone.0060007-Fons1]
  pUCYIT365N                                           Emr; E. coli-Lactobacillus shuttle vector; containing the emr promoter     GenBank accession No. AB119527
  pUCYIT-T7                                                                Emr, derivative of pUCYIT365N                          Ref. [@pone.0060007-Kuwahara1]
  pLEM415-ldhL-mRFP1                                         Emr, Ampr; pLEM415 derivative; containing ldhL-FLAG-mRFP1                      This study
  pLEM415-emr-mRFP1                                           Emr, Ampr; pLEM415 derivative; containing emr-FLAG-mRFP1                      This study
  pLEM415-P59-mRFP1                                           Emr, Ampr; pLEM415 derivative; containing P59-FLAG-mRFP1                      This study
  pUCYIT-S1                                                  Emr; derivative of pUCYIT-T7; containing the emr promoter                      This study
  pUCYIT-ldhL-mRFP1                                            Emr; pUCYIT-S1 derivative; containing ldhL-FLAG-mRFP1                        This study
  pUCYIT-emr-mRFP1                                   Emr; pUCYIT-S1 derivative containing FLAG-mRFP1 downstream of the emr gene             This study
  pUCYIT-P59-mRFP1                                              Emr; pUCYIT-S1 derivative; containing P59-FLAG-mRFP1                        This study

Emr, erythromycin resistant; Ampr, ampicillin resistant.

Transformation of Lactobacillus {#s2b}
-------------------------------

Preparation of Lactobacillus competent cells followed a standard protocol provided by Jean-Marc Chatel (MICALIS, INRA, Domaine de Vilvert, Jouy en Josas cedex, France) with some modifications. Specifically, 1 ml of an overnight culture of each Lactobacillus strain was diluted into 100 ml of fresh pre-warmed MRS broth. The culture was incubated at 37°C till the optical density (A~600~) reached 0.6--0.8. The culture was harvested by centrifugation. The cells were washed twice in 20 ml of ice-cold 1× SMEB (0.286 M sucrose, 1 mM MgCl~2~) before being resuspended in 1 ml of 1×SMEB. For each transformation, 0.5 µg of DNA was mixed with 200 µl of 100× concentrated bacteria. The bacterial suspension was electroporated using a Gene Pulser electroporator (Bio-Rad, California) in a cuvette with a 2-mm gap at 2.5 kV, 25 µFD and 200 Ω. Immediately after electroporation, 1 ml of MRS medium was added to the suspension. After incubation at 37°C overnight, serial dilutions were plated on MRS plates containing 25 µg/ml of erythromycin and incubated at 37°C for 2 to 3 days in anaerobic jars.

Construction of plasmids {#s2c}
------------------------

In this work, combinations of three promoters and two backbones were tested. Three promoters used: L-lactate dehydrogenase (ldhL) promoter of *Lactobacillus sakei* derived from pRV85 [@pone.0060007-Gory1], erythromycin resistance gene promoter (emr) derived from pUCYIT365N (GenBank accession No. AB119527) and P59 promoter [@pone.0060007-vanderVossen1]. The two backbones used were derived from pLEM415 [@pone.0060007-Fons1] and pUCYIT365N, respectively. All plasmids used in this work are summarized in [Table 1](#pone-0060007-t001){ref-type="table"}. pLEM415-ldhL-mRFP1 and the other two pLEM415-derived plasmids were generated following a procedure illustrated in [Fig.1](#pone-0060007-g001){ref-type="fig"}. Briefly, ldhL-FLAG-mRFP1 that contains the ldhL promoter and FLAG-mRFP1 was amplified by using a 3-round linking PCR technique ([Fig. 1](#pone-0060007-g001){ref-type="fig"}): a) In the first round of PCR, FLAG-mRFP1 containing FLAG tag and mRFP1 coding sequences was amplified from pRSET~B~-mRFP1 [@pone.0060007-Campbell1] using two primers 311-ldhl-mRFP and 352-mRFP-NBC ([Table 2](#pone-0060007-t002){ref-type="table"}); b) in the second round of PCR, the ldhL promoter sequence from pRV85 (gift of Monique Zagorec) was joined with FLAG-mRFP1 by allowing pRV85 and the product from the first round of PCR to anneal and extend; c) in the third round of PCR, the ldhL-FLAG-mRFP1 fragment was amplified from the second round of PCR product using two primers 351-ldhl-AXN and 352-mRFP-NBC ([Table 2](#pone-0060007-t002){ref-type="table"}). The product from the final round of linking PCR was cloned into pGEM-T (Promega, WI), giving rise to pGEM-T-ldhL -mRFP1. After verification by DNA sequencing, the ldhL-mRFP1 fragment was released from pGEM-T-ldhL-mRFP1 and inserted into pLEM415 (gift of Pascale Serror) between the same sites, leading to pLEM415-ldhL-mRFP1 ([Fig. 1](#pone-0060007-g001){ref-type="fig"}). The emr promoter was amplified from pUCYIT-T7 [@pone.0060007-Kuwahara1], a derivative of pUCYIT365N, and joined with FLAG-mRFP1 by linking PCR using three primers: 353-emr-AXN, 355-emr-mRFP and 352-mRFP-NBC ([Table 2](#pone-0060007-t002){ref-type="table"}). The P59 promoter sequence was amplified using three overlapping primers: 275-P59-a, 277-P59-b and 276-P59-c ([Table 2](#pone-0060007-t002){ref-type="table"}). The P59 promoter was joined with mRFP1 by linking PCR using three primers: 357-P59-AXN, 278-P59-mRFP and 352-mRFP-NBC ([Table 2](#pone-0060007-t002){ref-type="table"}). emr-FLAG-mRFP1 and P59-FLAG-mRFP1 were cloned into pLEM415 in a manner similar to ldhL-FLAG-mRFP1.

![Construction of Lactobacillus-based expression vectors.\
To generate pLEM415-ldhL-mRFP1, the ldhL promoter and FLAG-mRFP1 were joined by using a 3-round linking PCR technique. The resulting ldhL-FLAG-mRFP1 fragment was then cloned into pGEM-T. Finally, the fragment was released from pGEM-T and cloned into pLEM415. Other expression vectors described in this work were generated in a similar manner. Refer to [Materials and Methods](#s2){ref-type="sec"} for details.](pone.0060007.g001){#pone-0060007-g001}
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###### Primers used in this work.

![](pone.0060007.t002){#pone-0060007-t002-2}

  Primers                                                      Sequences                                 Application
  ---------------------------------- -------------------------------------------------------------- ----------------------
  **To amplify ldhL-FLAG-mRFP1:**                                                                   
  351-ldhl-AXN                             TTA[GGGCCCCTCGAGGCTAGC]{.ul}ACTGAGAAGTTGCTCTCCCCA         forward, linking PCR
  311-ldhl-mRFP                                TCCCCGGGTACCGGTAGAAAAAATGACTGGTGGACAGCAAA             forward, linking PCR
  352-mRFP-NBC                           TTA[ATCGATAGATCTGCTAGC]{.ul}TTAGGCGCCGGTGGAGTGGCGGCCCT      reverse, linking PCR
  **To amplify emr-FLAG-mRFP1:**                                                                    
  353-emr-AXN                             TTA[GGGCCCCTCGAGGCTAGC]{.ul}AGTGCAGTATCTTAAAATTTTGT        forward, linking PCR
  355-emr-mRFP                                 GTAATTAAGAAGGAGTGATTACATGACTGGTGGACAGCAAA             forward, linking PCR
  352-mRFP-NBC                           TTA[ATCGATAGATCTGCTAGC]{.ul}TTAGGCGCCGGTGGAGTGGCGGCCCT      reverse, linking PCR
  **To amplify the P59 promoter:**                                                                  
  275-P59-a                           GGTTTCTTCGCGCATTATAGTCCAAATTCTCTGTTATTCTTTTTTTCTAACTTTTTTCAC       forward, PCR
  277-P59-b                           TCTAACTTTTTTCACTGTAATTTAAGAACTGTCCCTCTCTATCCAAACTATCTTATATTA       forward, PCR
  276-P59-c                                       ATAATATAAGATAGTTTGGATAATATAAGATAGTT                    reverse, PCR
  **To amplify P59-FLAG-mRFP1:**                                                                    
  357-P59-AXN                             TTA[GGGCCCCTCGAGGCTAGC]{.ul}GGTTTCTTCGCGCATTATAGTCCA       forward, linking PCR
  278-P59-mRFP                           ACCCATTTGCTGTCCACCAGTCATGTAATCACCTCCTATAATATAAGATAGTTT      reverse, linking PCR
  352-mRFP-NBC                           TTA[ATCGATAGATCTGCTAGC]{.ul}TTAGGCGCCGGTGGAGTGGCGGCCCT      reverse, linking PCR

Restriction sites introduced in primers are underlined.

To generate pUCYIT derived plasmids, the T7 polymerase sequence in pUCYIT-T7 was replaced by a short sequence in between XhoI and NheI sites: CTGTGAGAA, giving rise to pUCYIT-S1. To generate pUCYIT-ldhL-mRFP1, ldhL-FLAG-mRFP1 was released from pGEM-T-ldhL-mRFP1 using NheI and cloned into pUCYIT-S1 at the same site. To generate pUCYIT-emr-mRFP1, FLAG-mRFP1 was released from pGEM-T-mRFP1 (Bao, S., unpublished) using XbaI and cloned into pUCYIT-S1 at the NheI site. To generate pUCYIT-P59-mRFP1, P59-FLAG-mRFP1 was released from pGEM-T-P59-mRFP1 using NheI and inserted into pUCYIT-S1 at the same site.

Determination of Lactobacillus distribution in the GI tract {#s2d}
-----------------------------------------------------------

Pregnant Sprague-Dawley rats were purchased from Taconic Laboratory, New York. Rats were housed in conventional solid-bottom polycarbonate cages (nominal floor area, 930 cm^2^) with standard stainless steel lids and hardwood chip bedding. Cages were changed once a week. Pelleted rat chow was provided ad libitum, and tap water was provided in a water bottle with a sipper tube. The environmental conditions in the animal room were as follows: temperature, 22 to 26 °C; relative humidity, 30% to 60%; lighting, 200 lm/m^2^ at cage level; lights on, 07:00 to 19:00. The female rats were allowed to deliver naturally. On postnatal day 1, a total of 38 pups were divided into three groups. In Group 1 (control group), 12 pups received orally a single dose of saline. In Group 2 (first experimental group), 20 pups received bacterial suspension containing about 6.5×10^8^ CFU of recombinant Lactobacillus transformed with pLEM-415-ldhL-mRFP1. In Group 3 (second experimental group), 6 pups received a single dose of bacterial suspension containing about 6.3×10^8^ CFU of *E. coli* DH5α transformed with pGEM-T-ldhL-mRFP1. At 24, 48, 72 and 96 h after oral administration, three pups from Group 1 and five from Group 2 were sacrificed. The stomach, small intestine, cecum and colon were dissected. Whole segments together with luminal contents were homogenized in phosphate-buffered saline (PBS), serially diluted and plated on MRS plates containing 25 µg/ml of erythromycin. Colonies were counted manually. All pups from Group 3 died at 24 h after oral feeding and no further experiments were performed. All procedures were carried out in accordance with the institutional guideline for the care and use of laboratory animals at the Icahn School of Medicine at Mount Sinai, New York.

Detection of mRFP1 {#s2e}
------------------

Images of Lactobacillus colonies on MRS plates were recorded using a Nikon SMZ 1500 dissecting microscope equipped with Nikon LV-TV camera (Nikon, Inc., New York). For fluorescence detection, the pellet of mRFP1 expressing cells was washed once and resuspended in PBS. Cells were fixed in 4% of paraformaldehyde. After washing once with PBS, fixed cells were mounted on a slide and examined using an Axioplan 2 epifluorescence microscope (Carl Zeiss, Inc., New York). Fluorescence images were recorded using an Axiocam digital camera (Carl Zeiss, Inc., New York).

For detection by the western blot, cells were collected from 24 h cultures inoculated using a single colony. Cell pellets were washed once and resuspended in 250 µl of STE solution (6.7% sucrose, 50 mM Tris and 1 mM EDTA). Cells were lysed by adding 250 µl of a lysis solution (200 mM NaOH and 1% SDS) in the presence of protease inhibitors for 5 minutes. Lysates were cleared by centrifugation. The total protein concentration was determined by using a BCA assay (Thermo Scientific, New York). An equal amount of protein in a total of 0.9 µg from each sample was loaded onto an 8% SDS-PAGE gel. Proteins were transferred onto a polyvinylidene difluoride (PVDF) membrane (Roche, Indiana) using a Bio-Rad electrotransfer system (Bio-Rad, California). The FLAG-mRFP1 protein was detected using an M2 anti-FLAG antibody (Sigma-Aldrich, Missouri). An anti-mouse IgG-HRP conjugate (Cell Signaling, Massachusetts) was used as the secondary antibody. Chemical luminescence signals were captured using the Fujifilm LAS-3000 imaging system equipped with a digital camera (Fuji Medical Systems USA, Connecticut). Intensities of proteins bands were quantified using ImageJ [@pone.0060007-Schneider1].

Results {#s3}
=======

Expression of mRFP1 at a high level in *Lactobacillus casei* {#s3a}
------------------------------------------------------------

A green fluorescent protein (GFP) and its variants have been broadly used as a reporter or marker. However, a high rate of fluorescence quenching has been observed in GFP at acidic pH [@pone.0060007-Tsien1]. Since Lactobacillus cultures produce lactic acid, detection of GFP in Lactobacillus in some cases has been problematic [@pone.0060007-Lizier1]. To circumvent this problem, in this study we used mRFP1, a red fluorescent protein, known to tolerate a low pH [@pone.0060007-Campbell1]. To achieve a high level of protein expression in Lactobacillus, we tested the impact of three promoters and two backbones on protein expression since choices of the promoter and the backbone often have a significant impact on the expression level of a target gene. Each construct was electroporated into *Lactobacillus casei*. A high level of expression was observed with the ldhL promoter. The highest level of mRFP1 expression was found with pLEM415-ldhL-mRFP1, a construct that combines the pLEM415 backbone and the ldhL promoter ([Fig. 2A--B](#pone-0060007-g002){ref-type="fig"}). The mRFP1 expression was so high that bacterial colonies appeared pink under visible light ([Fig. 2C--D](#pone-0060007-g002){ref-type="fig"}). In contrast, a lower level of mRFP1 expression was observed with the emr promoter. The amount of the mRFP1 protein expressed by pLEM-emr-mRFP1 and pUCYIT-emr-mRFP1 was about 73% and 47%, respectively, of that by pLEM415-ldhL-mRFP1 ([Fig. 2A--B](#pone-0060007-g002){ref-type="fig"}). A substantially lower level of expression was observed with the P59 promoter ([Fig. 2A--B](#pone-0060007-g002){ref-type="fig"}): levels of mRFP1 expressed by pLEM415-P59-mRFP1 and pUCYIT-P59-mRFP1 were only 18% and 11%, respectively, of that by pLEM415-ldhL-mRFP1. The combination of the pUCYIT365N backbone and the P59 promoter led to the lowest level of expression.

![Different expression levels of Lactobacillus-based expression vectors.\
A) Different levels of mRFP1 expression in *Lactobacillus casei* were detected by Western blot. A total of 0.9 µg of the whole lysate was loaded into each lane. Lane 1, pLEM415-ldhL-mRFP1; lane 2, pLEM415-emr-mRFP1; lane 3, pLEM415-P59-mRFP1; lane 4, pUCYIT-ldhL-mRFP1; lane 5, pUCYIT-emr-mRFP1; lane 6, pUCYIT-P59-mRFP1. B) Quantification of band intensities from Western blot in Panel A. The expression level of pLEM415-ldhL-mRFP1 was set to 100%. Sample numbers correspond to lanes shown in Panel A. C) Wild type *Lactobacillus casei* colonies under visible light. D) Colonies of *Lactobacillus casei* transformed with pLEM415-ldhL-mRFP1 appeared pink under visible light. Scale bars, 100 µm.](pone.0060007.g002){#pone-0060007-g002}

Due to its ability to express an exogenous protein at a high level in *Lactobacillus casei*, pLEM415-ldhL-mRFP1 was used to label *Lactobacillus casei* for further analyses. In fact, the high level of mRFP1 expression was not limited to *Lactobacillus casei*. When pLEM415-ldhl-mRFP1 was transformed into *Lactobacillus delbruekii* and *Lactobacillus acidophilus*, an equivalent level of mRFP1 was also observed ([Fig. 3A--D](#pone-0060007-g003){ref-type="fig"} and data not shown) and the colonies appeared pink under visible light, indicating pLEM415-ldhL-mRFP1 can be broadly utilized to label Lactobacillus.

![mRFP1 can be expressed broadly in Lactobacillus.\
The pLEM415-ldhL-mRFP1 vector was transformed into *L. casei* (B) and *L. delbrueckii* (D). mRFP1 was detected in both strains. Wild type strains were used as control (A,C). mRFP1 expression (red) is shown in the left panels and DIC images (purple) in the middle. Merged views are shown in the right panels. Scale bars, 20 µm.](pone.0060007.g003){#pone-0060007-g003}

Dynamic localization of *Lactobacillus casei* in the GI tract of neonatal rats {#s3b}
------------------------------------------------------------------------------

To test whether *Lactobacillus casei* can be retained in the GI tract of neonates, we introduced 6.5×10^8^ CFU of mRFP1-labeled *Lactobacillus casei* into neonatal rats on post-natal day 1 by gavage. At 24 h after oral administration of a single dose of Lactobacillus, about 3% of bacteria (1.9×10^7^ CFU) were retained in the GI tract without taking into account proliferation of the bacteria in the GI tract. These bacteria were found across all segments of the GI tract ([Fig. 4A--C](#pone-0060007-g004){ref-type="fig"}), but bacterial distributions were not even along the GI tract. In fact, a larger number of *Lactobacillus casei* presided in the stomach and small intestine than in the cecum and colon: about 30% (5.6×10^6^ CFU) and 35% of bacteria (6.7×10^6^ CFU) were found in the stomach and small intestine compared with 14% (2.6×10^6^ CFU) and 20% (3.6×10^6^ CFU) in the cecum and colon, respectively ([Fig. 4D](#pone-0060007-g004){ref-type="fig"}). This pattern is very reminiscent of natural distribution of Lactobacillus in the human GI tract where Lactobacillus predominates in the small intestine in some elderly individuals [@pone.0060007-Hayashi1]. This distribution pattern in the neonatal rats largely remains unchanged till 72 h after oral feeding. At 48 h, the total bacteria retained in the GI tract dropped to 0.5% (3.4 ×10^6^ CFU) ([Fig. 4D](#pone-0060007-g004){ref-type="fig"}). At 72 h, only very few bacteria (about 0.1%) were found in the GI tract ([Fig. 4D](#pone-0060007-g004){ref-type="fig"}). At 96 h, recombinant *Lactobacillus casei* was almost undetectable using our assay. Although these colonies retained the antibiotic resistance, we observed that only about 31% of colonies preserved fluorescence (n = 352) when a total of 1144 colonies were examined. It is not clear why over 2/3 of colonies retained the antibiotic resistance but lost fluorescence; we are currently investigating this issue. Noticeably, during the course of this study, no mortality was observed in neonatal rats treated with either saline or recombinant Lactobacillus. In contrast, all neonatal rats treated with the *E. coli* DH5α strain transformed with pGEM-T-ldhL-mRFP1 died within 24 h after gavage (n = 6), precluding its use as a delivery vehicle. Taken together, these results indicate that a portion of *Lactobacillus casei* can be retained in the GI tract of neonatal rats for at least 24 hours.

![Dynamic distribution of Lactobacillus in the GI tract of neonatal rats.\
Neonatal rats were fed with *L. casei* expressing mRFP1. Animals were sacrificed on Days 1, 2, 3 and 4 after gavage. The gastrointestinal homogenates were diluted and plated on MRS plate in the presence of erythromycin. Control rats were fed with saline only. Homogenates from experimental groups were plated on the left half of each plate and those from controls on the right half (A--C). Colonies were found in animals fed with labeled bacteria on Day 1. A) Stomach; B) cecum; C) colon. Scale bars, 10 mm. D) Entire colony counts. Samples were collected on Days 1 (blue), 2 (red) and 3 (green). Note: standard deviation was used to measure variability.](pone.0060007.g004){#pone-0060007-g004}

Discussion {#s4}
==========

In this study, we achieved a high level of protein expression in Lactobacillus by combining an ldhL promoter from *Lactobacillus sakei* with a backbone from pLEM415. In addition, we examined the expression of mRFP1 in 3 strains of Lactobacillus: *Lactobacillus casei*, *Lactobacillus delbrueckii* and *Lactobacillus acidophilus*. Expression levels of mRFP1 in all these strains were high. Using *Lactobacillus casei* that expressed mRFP1, we showed that a portion of the recombinant bacteria was retained in the GI tract of neonatal rats for at least 24 hours. Our results indicate that the recombinant Lactobacillus has the potential to be used as a vehicle for the delivery of therapeutic agents to the mucosa of GI tract.

Low levels of protein expression in Lactobacillus have hindered the wide application of Lactobacillus in therapeutic design. As a result, in the past decade many efforts have been made to improve the level of protein expression in this genus of Gram-positive bacteria. To date, constitutive expression of GFP in Lactobacillus has been reported [@pone.0060007-Lizier1], [@pone.0060007-Yu1]. However, GFP protein is not detectable under visible light and therefore its detection requires a fluorescence microscope. In addition, GFP and its variants are often sensitive to acidic pH. Due to quenching of GFP at a low pH [@pone.0060007-Tsien1], detection even with a microscope has been problematic. Although in some instances the GFP protein expressed in Lactobacillus can be visualized after taking additional measures such as neutralizing cells with a neutral buffer [@pone.0060007-Lizier1], the degree of success with these measures has been variable in our hands. To overcome these problems, we have used mRFP1 as a reporter, which is known to be stable at a low pH [@pone.0060007-Campbell1]. To achieve a high level of protein expression in Lactobacillus, we have tested different combinations of two backbones and three promoters. We found for a given backbone the ldhL promoter overall yielded the highest level of reporter expression and the P59 promoter the lowest. The emr promoter yielded an intermediate level of reporter expression. For a given promoter, the pLEM415 backbone conferred a higher level of expression than pUCYIT365N backbone. Consistently, the combination of the ldhL promoter and pLEM415 backbone yielded the highest level and the combination of the P59 promoter and pUCYIT365N backbone led to the lowest level of protein expression. While different expression levels conferred by different promoters with a given backbone clearly indicate differential strengths of the promoters, the reason why the same promoter gave rise to different levels of protein expression when combined with different backbones may not be straightforward. At this stage, it is not clear whether the copy number of pLEM415 was higher than that of pUCYIT365N in a host bacterial strain or whether the secondary structure of plasmid DNA resulting from a particular combination makes the same promoter in pLEM415 more accessible to the transcriptional machinery than in pUCYIT365N. Of note also is the unusual migrating behavior of the FLAG-mRFP1 protein, which has a molecular weight of 28 kDa. In a Western blot, this protein migrated at 65 kDa ([Fig. 2A](#pone-0060007-g002){ref-type="fig"}). One possibility is that the stop codon used in these constructs was leaky, leading to a fusion protein that is larger than FLAG-mRFP1. Alternatively, FLAG-mRFP1 formed a dimer under the SDS-PAGE condition. Currently we do not have any further evidence to distinguish these possibilities.

Our results demonstrate that Lactobacillus can be retained in all segments of the gastro-intestinal tract in neonatal rats for at least 24 hours after oral administration. In particular, a larger number of the recombinant bacteria were found in the stomach and small intestine than in the cecum and colon. One possibility is that the stomach and small intestine are preferred segments for Lactobacillus to colonize since Lactobacillus predominates in the small intestine in some individuals [@pone.0060007-Hayashi1]. Alternatively, these results may reflect larger luminal surface areas of the stomach and small intestine than those of the cecum and colon. Further studies are needed to clarify this issue.

Notwithstanding this, we have noticed that the retention rate of Lactobacillus is low in the GI tract of neonatal rats. Even without taking into account proliferation of Lactobacillus *in vivo*, only about 3.0% of Lactobacillus was retained in the GI tract at 24 h after oral feeding. From a clinical perspective, a low retention rate may actually be advantageous since complete removal of recombinant Lactobacilli from the GI tract after oral administration within a limited period of time will be essential for eliminating any potential unwanted long-lasting side effect of recombinant Lactobacillus on the host after therapeutic treatments. On the other hand, for therapeutic purposes, a retention rate of 3% may not be large enough to elicit strong immune responses in certain applications. One way to address this issue could be to administer neonates with multiple doses of recombinant Lactobacillus. Since Lactobacillus inhabits the small intestine, cecum and colon in humans [@pone.0060007-Hayashi1], [@pone.0060007-Marteau2], [@pone.0060007-Thadepalli1], an alternative approach is to use Lactobacillus species with a high capacity to colonize the human GI tract. Further studies are needed to isolate those species that are also capable of expressing a target protein at a desired level. Notably, during the course of this study, no mortality was observed in neonatal rats fed with Lactobacillus. In contrast, all neonates administered with the transformed E. coli DH5α strain died within 24 hours after gavage, precluding the use of *E. coli* as a vehicle in neonates. Taken together, our results indicate the Lactobacillus is safe and has the potential to be used as a vehicle to deliver therapeutic agents to the gastro-intestinal tract of neonates.
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